The Center for Biosimilars® recaps the top news for the week of August 13, 2018.
Transcript:
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of August 13.
Number 5: AbbVie has filed suit against biosimilar developer Sandoz over its proposed Humira biosimilar.
Number 4: Fifty-two-week results of a phase 3 study, which included a switch from Humira to SB5, show that switching led to no change in treatment-emergent adverse events.
Number 3: The clinical director of Ireland’s health technology assessment body has called for all new patients to start treatment with biosimilars rather than with reference products.
Number 2: The Federal Trade Commission has called on the FDA to use its authority to foster biosimilar competition.
Number 1: CVS Caremark says that it will use data from the Institute for Clinical and Economic Review in making coverage decisions.
Finally, last week, our e-newsletter asked whether you think that the United States should follow Australia’s lead in using “uptake drivers” for biosimilars.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.